OKYO Pharma Limited (OKYO) Stock Analysis & Investment Frameworks
OKYO Pharma Limited (OKYO) stock analysis on Invetso. Review OKYO Pharma Limited’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
OKYO Pharma Limited Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: GB
OKYO Pharma Limited Key Financial Metrics
- Market Cap: $77.14M
- Revenue: $N/A
- ROE: -200.67%
- ROIC: -74.59%
- Dividend Yield: N/A
About OKYO Pharma Limited
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
OKYO Pharma Limited Investment Frameworks
Invetso analyzes OKYO Pharma Limited (OKYO) across the following frameworks:
- OKYO Pharma Limited 10Y Growth Potential
- OKYO Pharma Limited Scenario Analysis
- OKYO Pharma Limited Risks & Opportunities
- OKYO Pharma Limited Economic Moat
- OKYO Pharma Limited Business Model
- OKYO Pharma Limited Management
- OKYO Pharma Limited SWOT Analysis
- OKYO Pharma Limited Porter's 5 Forces
- OKYO Pharma Limited PESTLE Analysis
- OKYO Pharma Limited ESG Analysis